OBJECTIVE: To examine the role of tumor necrosis factor-alpha (TNF-alpha) in producing acute inflammatory lung injury after hemorrhage and resuscitation. DESIGN: Prospective, controlled animal study. SETTING: Research laboratory. SUBJECTS: Male BALB/c mice. INTERVENTIONS: Treatment with rat antimouse monoclonal anti-TNF-alpha antibodies or control rat immunoglobulin G 1 hr after 30% blood volume hemorrhage and resuscitation. MEASUREMENTS AND MAIN RESULTS: Therapy with monoclonal anti-TNF-alpha antibodies prevented the posthemorrhage increases in pulmonary TNF-alpha and interferon-gamma protein levels that normally occur after blood loss. Administration of monoclonal anti-TNF-alpha antibodies also diminished the increases in interleukin-1 beta, interleukin-6, and interleukin-10 mRNA, but not the increases in TNF-alpha and interferon-gamma mRNA, which are found in the lungs following hemorrhage. In addition, therapy with monoclonal anti-TNF-alpha antibodies was associated with significant improvement in the histologic parameters of posthemorrhage lung injury, particularly intra-alveolar hemorrhage and pulmonary vascular congestion. CONCLUSIONS: These results indicate that TNF-alpha has an important role in the development of acute inflammatory lung injury after blood loss. Blockade of TNF-alpha with monoclonal antibodies significantly reduces hemorrhage-induced lung injury.
OBJECTIVE: To examine the role of tumor necrosis factor-alpha (TNF-alpha) in producing acute inflammatory lung injury after hemorrhage and resuscitation. DESIGN: Prospective, controlled animal study. SETTING: Research laboratory. SUBJECTS: Male BALB/c mice. INTERVENTIONS: Treatment with rat antimouse monoclonal anti-TNF-alpha antibodies or control rat immunoglobulin G 1 hr after 30% blood volume hemorrhage and resuscitation. MEASUREMENTS AND MAIN RESULTS: Therapy with monoclonal anti-TNF-alpha antibodies prevented the posthemorrhage increases in pulmonary TNF-alpha and interferon-gamma protein levels that normally occur after blood loss. Administration of monoclonal anti-TNF-alpha antibodies also diminished the increases in interleukin-1 beta, interleukin-6, and interleukin-10 mRNA, but not the increases in TNF-alpha and interferon-gamma mRNA, which are found in the lungs following hemorrhage. In addition, therapy with monoclonal anti-TNF-alpha antibodies was associated with significant improvement in the histologic parameters of posthemorrhage lung injury, particularly intra-alveolar hemorrhage and pulmonary vascular congestion. CONCLUSIONS: These results indicate that TNF-alpha has an important role in the development of acute inflammatory lung injury after blood loss. Blockade of TNF-alpha with monoclonal antibodies significantly reduces hemorrhage-induced lung injury.
Authors: Jillian R Richter; Jeffrey M Sutton; Ritha M Belizaire; Lou Ann Friend; Rebecca M Schuster; Taylor A Johannigman; Steven G Miller; Alex B Lentsch; Timothy A Pritts Journal: Shock Date: 2014-12 Impact factor: 3.454
Authors: Kristian Fog Nielsen; Kati Huttunen; Anne Hyvärinen; Birgitte Andersen; Bruce B Jarvis; Maija-Riitta Hirvonen Journal: Mycopathologia Date: 2002 Impact factor: 2.574
Authors: Nadine Beckmann; Jeffrey M Sutton; Richard S Hoehn; Peter L Jernigan; Lou Ann Friend; Taylor A Johanningman; Rebecca M Schuster; Alex B Lentsch; Charles C Caldwell; Timothy A Pritts Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-02-26 Impact factor: 5.464
Authors: Rajaie Namas; Ali Ghuma; Andres Torres; Patricio Polanco; Hernando Gomez; Derek Barclay; Lisa Gordon; Sven Zenker; Hyung Kook Kim; Linda Hermus; Ruben Zamora; Matthew R Rosengart; Gilles Clermont; Andrew Peitzman; Timothy R Billiar; Juan Ochoa; Michael R Pinsky; Juan Carlos Puyana; Yoram Vodovotz Journal: PLoS One Date: 2009-12-22 Impact factor: 3.240